The pharmaceutical industry plays an important role in improving Britain’s health and supporting economic growth by developing innovative, life-saving medicines.


The American Pharmaceutical Group (APG) represents the US research-based bio-pharmaceutical companies with a presence in the UK. The Group works to promote a greater understanding of the value of our member companies to people’s health and the UK economy, as we seek a receptive environment for inward investment and appropriate access, uptake and use of innovative medicines by the NHS.

American companies with a UK heritage

The pharmaceutical industry is a major source of investment and an important part of Britain’s industrial heritage. The American companies that comprise the APG have a long-standing commitment to the UK and play an important role in delivering the UK’s life sciences capacity. The eleven APG member companies support around 14,000 highly skilled jobs and are based across over 40 regional sites covering research and development (R&D), manufacturing, packaging and commercial operations.

APG member companies are at the forefront of developing innovative treatments for patients. These include medicines  to treat high cholesterol levels, mental health, cancer rheumatoid arthritis and hypertension. APG members invest more than £792 million in R&D each year and launched 20 new medicines in the UK between 2011 and 2015. In 2017 alone, the APG is conducting more than 500 clinical trials in the UK, providing over 24,000 patients with the opportunity to benefit from innovative medicine.

Although the UK accounts for just 2 per cent of members’ global sales, APG companies provide the equivalent of 13 per cent of jobs in the UK pharmaceutical industry, and 17 per cent  of R&D expenditure. With strong global competition for pharmaceutical investment , the APG works to ensure the UK is well-positioned to retain its share.

The APG’s role

Established in 1985, the APG is a voice for its members’ corporate headquarters and seeks a dialogue between the US biopharmaceutical industry, the UK Government and wider stakeholders. The APG works closely with the industry’s trade body, the Association of the British Pharmaceutical Industry, and as a group of US-based companies, the APG is able to bring a unique perspective to policy debates.